Newly discovered gene fusion may improve prostate cancer diagnosis
July 24th, 2009 - 6:09 pm ICT by ANIWashington, July 24 (ANI): Researchers have found a new gene fusion that is highly expressed in a subset of prostate cancers-a discovery that could lead to more accurate prostate cancer testing and new targets for potential treatments.
According to researchers from NewYork-Presbyterian Hospital/Weill Cornell Medical Center, gene fusions - a hybrid gene formed from two previously separated genes - may be at the root of what causes cancer cells to grow more quickly than normal cells.
The new findings are exciting because, unlike two previously discovered fusions, the new fusion, called NDRG1-ERG, produces a protein that may be a potential target for drug therapies.
“The prostate cancer gene fusions, and proteins they produce, are important because they serve as a cancer-specific marker. Currently, PSA testing is the standard of care, yet it is not accurate enough to predict prostate cancer, because many men may have an elevated PSA level, but have benign conditions such as inflammation of the prostate,” said Dr. Mark A. Rubin.
He said that it is important to distinguish harmful cancer from non-lethal diseases, such as benign prostatic hyperplasia, or enlarged prostate disease that exhibits similar symptoms to prostate cancer, in order to provide effective care.
Gen-Probe, a biotechnology diagnostics company, has licensed the new technology and is currently working towards developing urine tests to screen for gene fusions as a means of improving upon the current standard PSA test.
Rubin has earlier described the discovery of the TMPRSS2-ERG fusion found in 45 percent of prostate cancers.
However, the new gene fusion, although only seen in 5 percent of prostate cancers, is the only one of this fusion class that is predicted to produce a protein.
This fusion protein may be a target for drug therapy and could help target the other more common gene fusions.
“In the future, these fusions, specific to certain types of prostate cancer, may help physicians prescribe tailored therapies for their patients by avoiding the trial and error that is often associated with cancer treatments,” said Rubin.
He added: “We believe this is a first step toward providing patients with specific therapies that target individual cancer variants, and hope these findings will help doctors diagnose a patient’s specific disease.”
The study has been published in the journal Neoplasia. (ANI)
- Gene fusion is the 'smoking gun' in the development of prostate cancer: Study - May 19, 2010
- Scientists reveal prostate cancer's multiple personalities - Nov 04, 2010
- Drug for rare childhood cancer may help prevent prostate cancer spread - Apr 30, 2011
- Researchers look at new treatment for prostate cancer - Nov 15, 2010
- Male sex hormones that mutate in prostate cancer identified - Nov 15, 2010
- New test accurately detects aggressive prostate cancer - Apr 07, 2011
- Full genetic blueprint of multiple prostate tumors unveiled - Feb 10, 2011
- Surgery effective for aggressive prostate cancer patients - Sep 28, 2010
- Early warning signs for prostate cancer identified - Nov 07, 2010
- Why PSA levels reflect prostate cancer progression - Jan 14, 2011
- New ultrasound technology can accurately spot prostate cancer tumours - Dec 09, 2010
- 'Watchful waiting' often best strategy for low-risk prostate cancer - Jun 19, 2010
- DNA test to detect early bowel cancer could be 1 step closer - Mar 05, 2011
- Scientists discover potential new drug therapy for kidney diseases - Apr 27, 2011
- How 'triggering event' in cancer occurs - Oct 30, 2009
Tags: benign conditions, benign prostatic hyperplasia, cancer cells, cornell medical center, elevated psa level, fusion protein, gene fusion, inflammation of the prostate, lethal diseases, presbyterian hospital, prostate cancer, prostate cancer diagnosis, prostate cancer gene, prostate cancers, prostate disease, psa test, standard psa, target, weill cornell medical, weill cornell medical center